JP2025515029A - 血管透過性の選択的調節のための組成物及び方法 - Google Patents
血管透過性の選択的調節のための組成物及び方法 Download PDFInfo
- Publication number
- JP2025515029A JP2025515029A JP2024564653A JP2024564653A JP2025515029A JP 2025515029 A JP2025515029 A JP 2025515029A JP 2024564653 A JP2024564653 A JP 2024564653A JP 2024564653 A JP2024564653 A JP 2024564653A JP 2025515029 A JP2025515029 A JP 2025515029A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338359P | 2022-05-04 | 2022-05-04 | |
| US63/338,359 | 2022-05-04 | ||
| US202363444520P | 2023-02-09 | 2023-02-09 | |
| US202363444521P | 2023-02-09 | 2023-02-09 | |
| US63/444,520 | 2023-02-09 | ||
| US63/444,521 | 2023-02-09 | ||
| US202363495763P | 2023-04-12 | 2023-04-12 | |
| US202363495765P | 2023-04-12 | 2023-04-12 | |
| US63/495,765 | 2023-04-12 | ||
| US63/495,763 | 2023-04-12 | ||
| PCT/US2023/066549 WO2023215787A1 (en) | 2022-05-04 | 2023-05-03 | Compositions and methods for selective regulation of vascular permeability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515029A true JP2025515029A (ja) | 2025-05-13 |
| JP2025515029A5 JP2025515029A5 (cg-RX-API-DMAC7.html) | 2026-05-15 |
Family
ID=88647182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564653A Pending JP2025515029A (ja) | 2022-05-04 | 2023-05-03 | 血管透過性の選択的調節のための組成物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250282885A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4519320A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515029A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215787A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017224122B2 (en) * | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
| JP2023537452A (ja) * | 2020-05-22 | 2023-09-01 | イエール ユニバーシティ | 血管漏出を処置するための方法および組成物 |
| AU2021328375A1 (en) * | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
-
2023
- 2023-05-03 WO PCT/US2023/066549 patent/WO2023215787A1/en not_active Ceased
- 2023-05-03 EP EP23800204.2A patent/EP4519320A1/en active Pending
- 2023-05-03 JP JP2024564653A patent/JP2025515029A/ja active Pending
- 2023-05-03 US US18/862,505 patent/US20250282885A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023215787A8 (en) | 2024-11-14 |
| EP4519320A1 (en) | 2025-03-12 |
| US20250282885A1 (en) | 2025-09-11 |
| WO2023215787A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11680100B2 (en) | B7-H3 antibody, antigen-binding fragment thereof and medical use thereof | |
| JP6843868B2 (ja) | Pd−1結合タンパク質及びその使用方法 | |
| US20210069325A1 (en) | Methods of treating immune disorders using pd-1 binding proteins | |
| US10766958B2 (en) | Methods of treating vitiligo using PD-1 binding antibodies | |
| EP3882268A1 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
| US7371381B2 (en) | Anti-galanin antibodies and uses thereof | |
| CN102300997B (zh) | Toll样受体3拮抗剂 | |
| KR20240128132A (ko) | 중화 항-tl1a 단일 클론 항체 | |
| CN110790839B (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
| WO2020063660A1 (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
| JP7672532B2 (ja) | アイソフォーム選択的抗tgf-ベータ抗体及び使用方法 | |
| JP2023510787A (ja) | 抗angptl3抗体及びその応用 | |
| JP2026081251A (ja) | 抗trem-1抗体およびその使用 | |
| US20250282885A1 (en) | Compositions and methods for selective regulation of vascular permeability | |
| EP3990490A1 (en) | Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof | |
| JP2024507823A (ja) | 免疫監視を増強するために制御性t細胞を標的化するための材料及び方法 | |
| WO2022256739A2 (en) | Antibody specific for bcl-6 and methods of use | |
| WO2025101747A1 (en) | Methods and compositions for treatment of pulmonary hypertension | |
| WO2025201517A1 (zh) | 抗cd93抗体、其抗原结合片段及其应用 | |
| WO2026030235A1 (en) | Methods and compositions for treatment of cytokine release syndrome | |
| HK40045560A (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260501 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260501 |